Liver dysfunction in chronic heart failure: Prevalence, characteristics and prognostic significance

European Journal of Clinical Investigation

Volumn 42, Issue 2, 2012, Pages 153-163

  Poelzl, Gerhard ^a   Ess, Michael ^a   Mussner Seeber, Christine ^a   Pachinger, Otmar ^a   Frick, Matthias ^a   Ulmer, Hanno ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cardio hepatic syndrome; Chronic heart failure; Liver enzymes; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; SPIRONOLACTONE;

ADULT; ADVERSE OUTCOME; AGED; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; LABORATORY TEST; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84855505229     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02573.x     Document Type: Article

References (38)

1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-39.
2. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951;13:273-93.
3. de la Monte SM, Arcidi JM, Moore GW, Hutchins GM. Midzonal necrosis as a pattern of hepatocellular injury after shock. Gastroenterology 1984;86:627-31.
4. Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003;37:393-400.
5. Cogger VC, Fraser R, Le Couteur DG. Liver dysfunction and heart failure. Am J Cardiol 2003;91:1399.
6. Lefkowitch JH, Mendez L. Morphologic features of hepatic injury in cardiac disease and shock. J Hepatol 1986;2:313-27.
7. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003;82:392-406.
8. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002;6:947-67, viii-ix.
9. Kubo SH, Walter BA, John DH, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 1987;147:1227-30.
10. Vasconcelos LA, de Almeida EA, Bachur LF. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure. Arq Bras Cardiol 2007;88:590-5.
11. Dichtl W, Vogel W, Dunst KM, Grander W, Alber HF, Frick M et al. Cardiac hepatopathy before and after heart transplantation. Transpl Int 2005;18:697-702.
12. Poelzl G, Eberl C, Achrainer H, Doerler J, Pachinger O, Frick M et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail 2009;2:294-302.
13. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11:170-7.
14. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995;16:1613-8.
15. Shinagawa H, Inomata T, Koitabashi T, Nakano H, Takeuchi I, Naruke T et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J 2008;72:364-9.
16. Szygula-Jurkiewicz B, Wojnicz R, Lekston A, Duszanska A, Spinczyk B, Nowak J et al. [Effect of elevated bilirubin levels on the long-term outcome in patients with chronic heart failure due to hypertension]. Pol Arch Med Wewn 2007;117:227-33.
17. Heinze G, Schemper M. Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 2003;71:155-63.
18. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults. Circulation 2005;112:2130-7.
19. Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med 2009;47:1055-62.
20. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009;120:1784-92.
21. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
22. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002;90:1405-9.
23. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007;46:1063-70.
24. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000;140:111-20.
25. Richman SM, Delman AJ, Grob D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med 1961;30:211-25.
26. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010;16:84-90.
27. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-84.
28. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001;345:574-81.
29. Sun JP, James KB, Yang XS, Solankhi N, Shah MS, Arheart KL et al. Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities. Am J Cardiol 1997;80:1583-7.
30. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009;40:3422-7.
31. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114:1476-81.
32. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008;121:781-8.
33. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043-6.
34. Emdin M, Passino C, Michelassi C, Titta F, L'Abbate A, Donato L et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 2001;22:1802-7.
35. Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall J et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28, 838 middle-aged men and women. Eur Heart J 2006;27:2170-6.
36. Meisinger C, Doring A, Schneider A, Lowel H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006;189:297-302.
37. Strasak AM, Kelleher CC, Klenk J, Brant LJ, Ruttmann E, Rapp K et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76, 113 Austrian adults. Arterioscler Thromb Vasc Biol 2008;28:1857-65.
38. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699-708.